Article
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
The Lancet. Oncology - 1 Sept 2013
Shi Yuankai, Zhang Li, Liu Xiaoqing, Zhou Caicun, Zhang Li, Zhang Shucai, Wang Dong, Li Qiang, Qin Shukui, Hu Chunhong, Zhang Yiping, Chen Jianhua, Cheng Ying, Feng Jifeng, Zhang Helong, Song Yong, Wu Yi-Long, Xu Nong, Zhou Jianying, Luo Rongcheng, Bai Chunxue, Jin Yening, Liu Wenchao, Wei Zhaohui, Tan Fenlai, Wang Yinxiang, Ding Lieming, Dai Hong, Jiao Shunchang, Wang Jie, Liang Li, Zhang Weimin, Sun Yan
Abstract excerpt
BACKGROUND: Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib is non-inferior to gefitinib in patients with non-small-cell lung cancer. METHODS: In this randomised, double-blind, phase 3 non-inferiority trial we enrolled patients with advanced non-small-cell lung cancer from 27 sites in...
Topics
Join the communities discussing this publication.